6QC Stock Chart & Stats
€15.70
-€0.50(-2.48%)
At close: 4:00 PM EST
€15.70
-€0.50(-2.48%)
Day’s Range― - ―
52-Week Range€15.20 - €23.60
Previous CloseN/A
Volume0.00
Average Volume (3M)0.00
Market Cap
€975.07M
Enterprise Value€375.50K
Total Cash (Recent Filing)€42.23B
Total Debt (Recent Filing)€229.93B
Price to Earnings (P/E)21.6
Beta0.40
Next Earnings
Nov 16, 2026EPS Estimate
0.57Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)167.96
Shares Outstanding51,516,000
10 Day Avg. Volume0
30 Day Avg. Volume0
Financial Highlights & Ratios
PEG Ratio-0.52
Price to Book (P/B)1.11
Price to Sales (P/S)0.72
P/FCF Ratio24.19
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)2.51
Revenue Forecast (FY)€1.65B
Bulls Say, Bears Say
Bulls Say
Revenue Growth And Stable Gross MarginContinued revenue expansion alongside a stable gross margin indicates that Towa is retaining broadly consistent production economics as sales grow. This supports the durability of its generic-drug portfolio and provides a foundation for improving earnings if profitability pressures moderate.
Broad Generic Portfolio And In-house ManufacturingA broad portfolio across therapeutic areas can support customer reach and reduce reliance on any single medicine or treatment category. In-house manufacturing and ongoing development of off-patent products also give Towa an enduring operating platform for refreshing its product lineup.
Growing Equity BaseGrowth in shareholders’ equity provides some balance-sheet support and cushions the company against the pressure created by higher debt. Although leverage remains a concern, the larger equity base can help preserve operating continuity and provide some capacity to manage investment needs.
Bears Say
Sharp Profitability DeteriorationMaterial compression in net and EBIT margins means revenue growth is currently producing substantially less earnings than in earlier periods. Persistently weaker profitability would reduce internal funding capacity, limit returns on the business, and make recovery dependent on effective cost or product-mix improvement.
Higher Leverage Reduces FlexibilityThe substantial increase in debt has left Towa more financially burdened while profitability and ROE are lower. Higher leverage can constrain capital allocation, increase the importance of stable operating performance, and reduce flexibility to absorb further earnings weakness or fund growth.
Thin And Volatile Free Cash FlowWeak conversion of earnings into surplus cash limits the funds available for reinvestment, debt reduction, and shareholder returns. The history of negative free cash flow in several subsequent years also indicates that cash generation has not yet become a consistently dependable source of financial strength.
Towa Pharmaceutical Co News
6QC FAQ
What was Towa Pharmaceutical Co Ltd’s price range in the past 12 months?
Towa Pharmaceutical Co Ltd lowest stock price was €15.20 and its highest was €23.60 in the past 12 months.
What is Towa Pharmaceutical Co Ltd’s market cap?
Towa Pharmaceutical Co Ltd’s market cap is €975.07M.
When is Towa Pharmaceutical Co Ltd’s upcoming earnings report date?
Towa Pharmaceutical Co Ltd’s upcoming earnings report date is Nov 16, 2026 which is in 61 days.
How were Towa Pharmaceutical Co Ltd’s earnings last quarter?
Towa Pharmaceutical Co Ltd released its earnings results on Aug 06, 2026. The company reported €0.629 earnings per share for the quarter.
Is Towa Pharmaceutical Co Ltd overvalued?
According to Wall Street analysts Towa Pharmaceutical Co Ltd’s price is currently Overvalued.
Does Towa Pharmaceutical Co Ltd pay dividends?
Towa Pharmaceutical Co Ltd does not currently pay dividends.
What is Towa Pharmaceutical Co Ltd’s EPS estimate?
Towa Pharmaceutical Co Ltd’s EPS estimate is 0.57.
How many shares outstanding does Towa Pharmaceutical Co Ltd have?
Towa Pharmaceutical Co Ltd has 51,516,000 shares outstanding.
What happened to Towa Pharmaceutical Co Ltd’s price movement after its last earnings report?
Towa Pharmaceutical Co Ltd reported an EPS of €0.629 in its last earnings report. Following the earnings report the stock price went up 1.923%.
Which hedge fund is a major shareholder of Towa Pharmaceutical Co Ltd?
Currently, no hedge funds are holding shares in DE:6QC
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Towa Pharmaceutical Co Ltd
Towa Pharmaceutical Co., Ltd., along with its subsidiaries, is actively engaged in the entire pharmaceutical lifecycle within Japan, from researching and developing to manufacturing and marketing prescription medications, active pharmaceutical ingredients, and intermediate compounds. The company's extensive product offerings target critical therapeutic areas, including diabetes, digestive and nervous system disorders, and allergic conditions. Furthermore, their portfolio encompasses vitamins, antibiotics, and oncology treatments. With a comprehensive collection of approximately 700 distinct drug products, Towa Pharmaceutical Co., Ltd. was founded in 1951 and is headquartered in Osaka, Japan.
Technical Analysis
Kaken Pharmaceutical Co
―
Kissei Pharmaceutical Co
―
Mochida Pharmaceutical Co., Ltd.
―
KYORIN Pharmaceutical Co.,Ltd.
―
SAWAI GROUP HOLDINGS Co., Ltd.
―